New Phase 3b Psoriatic Arthritis (PsA) Data Show First-in-Class TREMFYA ® (guselkumab) Achieved Robust Joint Symptom Improvement and Complete Skin Clearance in Patients with Inadequate Response to Tumor Necrosis Factor Inhibition (TNFi-IR)
SPRING HOUSE, PENNSYLVANIA, June 2, 2021 – Today the Janssen Pharmaceutical Companies of Johnson & Johnson announced new efficacy and safety data for first-in-class TREMFYA® (guselkumab), including data from the first study evaluating a selective IL-23 inhibitor in adult patients with active PsA, all of whom had demonstrated inadequate response or intolerance to TNFi.1 In the COSMOS Phase 3b study, significantly higher proportions of patients treated with TREMFYA showed joint symptom improvement and complete skin clearance versus placebo at week 24 in this true TNFi-IRa patient population, which is often more...
Source: Johnson and Johnson - June 2, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

SEAVUE: Ustekinumab vs Adalimumab for Crohn's Disease SEAVUE: Ustekinumab vs Adalimumab for Crohn's Disease
For biologic-naive adults with moderate to severe Crohn's disease, treatment with either adalimumab or ustekinumab leads to similar outcomes, according to results of the head-to-head SEAVUE trial.Medscape Medical News (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - May 28, 2021 Category: Gastroenterology Tags: Gastroenterology News Source Type: news

Janssen Presents Results of First Head-to-Head Study of Biologic Therapies in Patients with Moderate to Severe Crohn ’s Disease
SPRING HOUSE, PENNSYLVANIA, May 23, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced efficacy and safety data for STELARA® (ustekinumab) in Crohn’s disease (CD) and ulcerative colitis (UC),1-4including data from the SEAVUE study, the first head-to-head study of biologic therapies in patients with CD, presented in a Clinical Science Late-Breaking Abstract Plenary session.1 SEAVUE data showed treatment with STELARA demonstrated high rates of clinical remission, corticosteroid-free remission, clinical response and endoscopic response through one year in biologic-naïve p...
Source: Johnson and Johnson - May 24, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Bimekizumab Tops Secukinumab for Plaque Psoriasis
MONDAY, April 26, 2021 -- For patients with moderate-to-severe plaque psoriasis, bimekizumab is noninferior and superior to secukinumab and adalimumab, according to two studies published online April 23 in the New England Journal of Medicine to... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 26, 2021 Category: Pharmaceuticals Source Type: news

Bimekizumab Tops Adalimumab for Plaque Psoriasis Bimekizumab Tops Adalimumab for Plaque Psoriasis
At week 16, 86.2% of those in the bimekizumab group had a PASI 90 response, compared with 47.2% in the adalimumab group.Medscape Medical News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - April 23, 2021 Category: Dermatology Tags: Dermatology News Source Type: news

New Phase 3 Data Showed First-in-Class TREMFYA ® (guselkumab) Provided Durable Complete Skin Clearance Through Five Years in Moderate to Severe Plaque Psoriasis (PsO) and Robust Joint Symptom Improvement Through 52 Weeks in Active Psoriatic Arthritis (PsA)
SPRING HOUSE, PENNSYLVANIA, April 23, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new Phase 3 data which showed TREMFYA® (guselkumab) sustained durable, complete skin clearance rates in a majority of adults with moderate to severe plaque psoriasis (PsO) through five years (252 weeks), a and improved disease activity and axial symptoms in adults with active psoriatic arthritis (PsA) through one year (52 weeks).1,2,3 These data are being presented at the American Academy of Dermatology Virtual Meeting Experience 2021, where Janssen will present a total of 22 abstracts. TREMF...
Source: Johnson and Johnson - April 23, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Wonder drug set to help millions of NHS patients
Adalimumab, known by the brand name Humira, dampens the inflammation that causes the joint pain and swelling of rheumatoid arthritis. (Source: the Mail online | Health)
Source: the Mail online | Health - April 17, 2021 Category: Consumer Health News Source Type: news

Efficacy and Safety of Adalimumab Biosimilar CT-P17 for RA Efficacy and Safety of Adalimumab Biosimilar CT-P17 for RA
Is this adalimumab biosimilar for the treatment of rheumatoid arthritis as safe and effective as the reference product?Arthritis Research & Therapy (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 26, 2021 Category: Consumer Health News Tags: Rheumatology Journal Article Source Type: news

Adalimumab Earns FDA Approval for Ulcerative Colitis in Children Adalimumab Earns FDA Approval for Ulcerative Colitis in Children
Adalimumab has received approval from the Food and Drug Administration for use in pediatric patients aged 5 years and older with moderately to severely active ulcerative colitis.FDA Approvals (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - March 3, 2021 Category: Gastroenterology Tags: Pediatrics News Alert Source Type: news

Humira (adalimumab) Receives FDA Approval to Treat Pediatric Patients Living with Moderately to Severely Active Ulcerative Colitis
NORTH CHICAGO, Ill., Feb. 24, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) approved Humira (adalimumab) for the treatment of moderately to severely active ulcerative colitis in pediatric... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - February 24, 2021 Category: Drugs & Pharmacology Source Type: news

Adalimumab Enhances Primary Wound Closure After HS Surgery Adalimumab Enhances Primary Wound Closure After HS Surgery
' Our experience suggests that under the effects of treatment with adalimumab, wound healing disorders with primary wound closure occur less often,'Gefion Girbig, MD, reported at the EADV Congress.Medscape Medical News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - February 3, 2021 Category: Dermatology Tags: Dermatology News Source Type: news

Drugmaker AbbVie reports 'strong' fourth-quarter and fiscal 2020 results
Strong sales of arthritis drug Humira and new Botox products helped in the quarter and fiscal year. (Source: bizjournals.com Health Care News Headlines)
Source: bizjournals.com Health Care News Headlines - February 3, 2021 Category: Health Management Authors: Ben Miller Source Type: news

Innovent Announces NMPA Granted New Indication Approval for SULINNO(R) (Adalimumab Injection) in China for the Treatment of Polyarticular Juvenile Idiopathic Arthritis
SAN FRANCISCO and SUZHOU, China, Nov. 23, 2020 -- (Healthcare Sales & Marketing Network) -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines fo... Biopharmaceuticals, Regulatory Innovent Biologics, SULINNO , adalimumab (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 23, 2020 Category: Pharmaceuticals Source Type: news

Covid-19: Anti-TNF drug adalimumab to be trialled for patients in the community, BMJ
The AVID-CC trial, funded through the Covid-19 Therapeutics Accelerator, will investigate whether adalimumab (two doses being evaluated) is effective in the treatment of adults in community care settings. Treatment will be delivered by Hospital at Home teams around the UK. (Source: Current Awareness Service for Health (CASH))
Source: Current Awareness Service for Health (CASH) - October 5, 2020 Category: Consumer Health News Source Type: news

Oxford to Study Anti-inflammatory Drug Humira as Potential COVID-19 Treatment Oxford to Study Anti-inflammatory Drug Humira as Potential COVID-19 Treatment
Oxford University said on Wednesday it would study whether the world's best-selling prescription medicine, adalimumab, was an effective treatment for COVID-19 patients.Reuters Health Information (Source: Medscape Critical Care Headlines)
Source: Medscape Critical Care Headlines - October 1, 2020 Category: Intensive Care Tags: Infectious Diseases News Source Type: news

Arthritis drug to be trialled as Covid treatment in UK care homes
Adalimumab could counter hyper-inflammation seen in severe coronavirus casesCoronavirus – latest updatesSee all our coronavirus coverageA commonly used arthritis drug is to be trialled with care home residents who have Covid, after it was observed that those taking it for their joint pains were less likely to end up in hospital with the virus.Older people in care homes, who often have some degree of dementia, tend not to do well in hospital, where they become more confused and may pick up infections. The trial will break new ground by giving the drug to people at care homes, where they can be supervised and monitored...
Source: Guardian Unlimited Science - September 29, 2020 Category: Science Authors: Sarah Boseley Health editor Tags: Coronavirus outbreak UK news Medical research Older people Social care Health NHS Drugs Infectious diseases Science Society Source Type: news

Secukinumab Not Superior to Adalimumab in Psoriatic Arthritis
No abstract available (Source: Lippincott's Bone and Joint Newsletter)
Source: Lippincott's Bone and Joint Newsletter - September 26, 2020 Category: Orthopaedics Tags: Snapshot Source Type: news

Innovent Announces NMPA Granted Marketing Approval for SULINNO(R) (Adalimumab Injection) in China
SAN FRANCISCO, U.S. and SUZHOU, China, Sept. 3, 2020 -- (Healthcare Sales & Marketing Network) -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medici... Biopharmaceuticals, Regulatory Innovent Biologics, SULINNO , adalimumab (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - September 3, 2020 Category: Pharmaceuticals Source Type: news

Hulio (Adalimumab-fkjp njection) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - July 16, 2020 Category: Drugs & Pharmacology Source Type: news

FDA Approves Hulio (adalimumab-fkjp), a Biosimilar to Humira
HERTFORDSHIRE, England and PITTSBURGH and TOKYO, July 9, 2020 /PRNewswire/ -- Mylan N.V. (NASDAQ: MYL) and Fujifilm Kyowa Kirin Biologics Co., Ltd. today announced that the U.S. Food and Drug Administration (FDA)... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - July 9, 2020 Category: Drugs & Pharmacology Source Type: news

Imraldi (Adalimumab-xxxx Injection, for Subcutaneous Use) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - May 18, 2020 Category: Drugs & Pharmacology Source Type: news

US regulator clears AbbVie’s $63bn deal for Allergan
Federal Trade Commission votes 3-2 to approve tie-up between makers of Botox and Humira (Source: FT.com - Drugs and Healthcare)
Source: FT.com - Drugs and Healthcare - May 6, 2020 Category: Pharmaceuticals Source Type: news

Determining Therapeutic Range of Anti-TNF Therapies in IBD Determining Therapeutic Range of Anti-TNF Therapies in IBD
This review describes the principles and process followed to define the target therapeutic ranges for infliximab and adalimumab in the treatment of inflammatory bowel disease.Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 6, 2020 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

More January U.S. price hikes take 2020 tally to over 330 drugs with higher cost
AbbVie Inc on Thursday raised the cost of rheumatoid arthritis treatment Humira, the world's top-selling medicine, joining other drugmakers that have now hiked U.S. prices of more than 330 prescription drugs for 2020, according to data analyzed by healthcare research firm 3 Axis Advisors. (Source: Reuters: Health)
Source: Reuters: Health - January 2, 2020 Category: Consumer Health News Tags: healthNews Source Type: news

Adalimumab in Pediatric Patients With Severe Plaque Psoriasis Adalimumab in Pediatric Patients With Severe Plaque Psoriasis
This analysis reports results from the first RCT comparing the efficacy and safety of the biologic adalimumab with methotrexate for severe plaque psoriasis in children.The British Journal of Dermatology (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - December 27, 2019 Category: Allergy & Immunology Tags: Dermatology Journal Article Source Type: news

EMA Panel Backs Adalimumab Biosimilar Amsparity EMA Panel Backs Adalimumab Biosimilar Amsparity
The CHMP has recommended approval of Pfizer's adalimumab biosimilar (Amsparity) for treatment of certain inflammatory and autoimmune disorders in adults and children.International Approvals (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - December 16, 2019 Category: Drugs & Pharmacology Tags: Rheumatology News Alert Source Type: news

Biosimilar for Crohn's Noninferior to Adalimumab Biosimilar for Crohn's Noninferior to Adalimumab
A patent dispute means that the marketing of a biosimilar for patients with inflammatory bowel disease will be delayed, despite approval by the US Food and Drug Administration, investigators report.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 15, 2019 Category: Consumer Health News Tags: Gastroenterology News Source Type: news

FDA approves Pfizer's biosimilar, ABRILADA ™ (adalimumab-afzb) for multiple inflammatory conditions
Pfizer Inc. (NYSE: PFE) announced the United States (U.S.) Food and Drug Administration (FDA) has approved ABRILADA™ (adalimumab-afzb), as a biosimilar to Humira® (adalimumab),(1) for the treatment of certain patients with rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult Crohn's disease, ulcerative colitis and plaque psoriasis.(2) (Source: World Pharma News)
Source: World Pharma News - December 2, 2019 Category: Pharmaceuticals Tags: Featured Pfizer Business and Industry Source Type: news

Abrilada (Adalimumab-afzb Injection, for Subcutaneous Use) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - December 2, 2019 Category: Drugs & Pharmacology Source Type: news

Abrilada (Adalimumab-afzb Injection, for Subcutaneous Use) - new on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - November 26, 2019 Category: Drugs & Pharmacology Source Type: news

Pfizer nabs FDA approval for Humira biosim
Abrilada is the fifth Humira biosimilar approved in the U.S. and will join generics from Mylan, Samsung Bioepis and Sandoz when AbbVie's blockbuster has its patent expire in 2023. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - November 19, 2019 Category: Pharmaceuticals Source Type: news

FDA Approves Abrilada (adalimumab-afzb), a Biosimilar to Humira
November 18, 2019 - Pfizer Inc. (NYSE: PFE) today announced the United States (U.S.) Food and Drug Administration (FDA) has approved Abrilada™ (adalimumab-afzb), as a biosimilar to Humira® (adalimumab),1 for the treatment of certain... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - November 18, 2019 Category: Drugs & Pharmacology Source Type: news

Statement from Sarah Yim, M.D., acting director of the Office of Therapeutic Biologics and Biosimilars in the FDA ’s Center for Drug Evaluation and Research, on FDA’s continued progress facilitating competition in the biologic marketplace with approval of 25th biosimilar product
FDA has taken another step to further foster biologics competition with the approval of 25th biosimilar, Abrilada (adalimumab - afzb), a biosimilar to Humira. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - November 15, 2019 Category: Drugs & Pharmacology Authors: FDA Source Type: news

ACR 2019: Lilly Presents 52-Week Head-to-Head (SPIRIT-H2H) Data from Taltz(R) (ixekizumab) Versus Humira(R) (adalimumab) Trial in Psoriatic Arthritis
Taltz demonstrated sustained effect when compared to Humira through 52 weeks in patients with active psoriatic arthritis INDIANAPOLIS, Nov. 12, 2019 -- (Healthcare Sales & Marketing Network) -- Eli Lilly and Company (NYSE: LLY) announced today the 52-w... Biopharmaceuticals Eli Lilly, Taltz, ixekizumab, psoriatic arthritis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 12, 2019 Category: Pharmaceuticals Source Type: news

China's Bio-Thera Gets Approval for Humira Biosimilar China's Bio-Thera Gets Approval for Humira Biosimilar
China's Bio-Thera Solutions Ltd has won a regulatory approval for its version of AbbVie Inc's blockbuster rheumatoid arthritis treatment Humira (adalimumab), paving the way for the first such biosimilar to enter the world's second-largest drug market.Reuters Health Information (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - November 9, 2019 Category: Allergy & Immunology Tags: Rheumatology News Source Type: news

China's Bio-Thera gets approval for Humira biosimilar
China's Bio-Thera Solutions Ltd has won a regulatory approval for its version of AbbVie Inc's blockbuster rheumatoid arthritis treatment Humira, paving the way for the first such biosimilar to enter the world's second-largest drug market. (Source: Reuters: Health)
Source: Reuters: Health - November 7, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

Novartis Arthritis Drug Falls Short in Challenge to Global Bestseller Novartis Arthritis Drug Falls Short in Challenge to Global Bestseller
Novartis said a trial fell short of producing statistical evidence that its anti-inflammatory drug Cosentyx (secukinumab) can beat the world's best-selling drug Humira (adalimumab) in treating a type of arthritis.Reuters Health Information (Source: Medscape Orthopaedics Headlines)
Source: Medscape Orthopaedics Headlines - November 5, 2019 Category: Orthopaedics Tags: Rheumatology News Source Type: news

Novartis Cosentyx ® shows encouraging results versus Humira® from first-of-its-kind head-to-head trial in psoriatic arthritis
Novartis, a leader in rheumatology and immuno-dermatology, announced results from the EXCEED head-to-head trial comparing Cosentyx® (secukinumab) to Humira®* (adalimumab) in patients with active psoriatic arthritis (PsA)[1]. While Cosentyx narrowly missed statistical significance for superiority in ACR 20, the primary endpoint of the EXCEED trial, it showed numerically higher results versus Humira®*[1]. (Source: World Pharma News)
Source: World Pharma News - November 4, 2019 Category: Pharmaceuticals Tags: Featured Novartis Business and Industry Source Type: news

Novartis arthritis drug " narrowly misses " against Humira
Novartis said a trial fell short of producing statistical evidence that its anti-inflammatory drug, Cosentyx, can beat the world's best-selling drug Humira in treating arthritis. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - November 1, 2019 Category: Pharmaceuticals Source Type: news

Risk for Birth Defects Not Increased With Adalimumab
FRIDAY, Nov. 1, 2019 -- Adalimumab exposure in pregnancy does not increase the risk for birth defects, according to a study published online Oct. 18 in PLOS ONE. Christina D. Chambers, from the University of California San Diego in La Jolla, and... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 1, 2019 Category: Pharmaceuticals Source Type: news

Novartis arthritis drug falls short in challenge to global bestseller
Novartis said a trial fell short of producing statistical evidence that its anti-inflammatory drug Cosentyx can beat the world's best-selling drug Humira in treating a type of arthritis. (Source: Reuters: Health)
Source: Reuters: Health - November 1, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

Therapeutic IBD Drug Concentrations May Vary With Different Assays Therapeutic IBD Drug Concentrations May Vary With Different Assays
In patients with inflammatory bowel disease (IBD), concentrations of infliximab and adalimumab varied depending on whether they were assessed with the Enzyme-Linked Immunosorbent Assay (ELISA) or the Homogeneous Mobility Shift Assay (HMSA), researchers found.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 22, 2019 Category: Consumer Health News Tags: Gastroenterology News Source Type: news

Study Suggests Adalimumab Exposure in Pregnancy Does Not Increase...
602 Pregnancies Examined by the Non-Profit Organization of Teratology Information Specialists(PRWeb October 18, 2019)Read the full story at https://www.prweb.com/releases/study_suggests_adalimumab_exposure_in_pregnancy_does_not_increase_birth_defects_risk/prweb16660500.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - October 18, 2019 Category: Pharmaceuticals Source Type: news

Humira, Rituxan Top List of U.S. Drugs With Biggest Price Increases -report Humira, Rituxan Top List of U.S. Drugs With Biggest Price Increases -report
Reuters Health Information (Source: Medscape Hiv-Aids Headlines)
Source: Medscape Hiv-Aids Headlines - October 10, 2019 Category: Infectious Diseases Tags: Public Health & Prevention News Source Type: news

Humira, Rituxan top list of U.S. drugs with biggest price increases: report
AbbVie Inc's rheumatoid arthritis drug Humira and Roche Holding AG's cancer drug Rituxan topped a list of seven treatments whose combined 2017 and 2018 price hikes accounted for a $5.1 billion increase in U.S. spending, a report released on Tuesday showed. (Source: Reuters: Health)
Source: Reuters: Health - October 8, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

Cyltezo (Adalimumab-ADBM Injection, for Subcutaneous Use) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - September 26, 2019 Category: Drugs & Pharmacology Source Type: news

Vedolizumab Beats Adalimumab for Ulcerative Colitis Remissions
WEDNESDAY, Sept. 25, 2019 -- In moderate-to-severe ulcerative colitis, vedolizumab is superior to adalimumab for achieving clinical remission and endoscopic improvement, but not corticosteroid-free clinical remission, and ustekinumab is superior to... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 25, 2019 Category: Pharmaceuticals Source Type: news

Adalimumab procurement framework extended
NHS England has extended the procurement framework for adalimumab by four months to 31 March 2020. (Source: NHS Networks)
Source: NHS Networks - September 8, 2019 Category: UK Health Source Type: news

NHS saves £300MILLION in a year by telling doctors to stop giving out expensive branded medications
Hospitals spent £290million on adalimumab - a drug primarily used to treat arthritis but also given to patients with Crohn's disease - in 2018/19. (Source: the Mail online | Health)
Source: the Mail online | Health - August 31, 2019 Category: Consumer Health News Source Type: news

These are the top 25 costliest prescription drugs for Oregon insurers
Humira is the best-selling medicine in the world and a gold mine for drug maker AbbVie, bringing in $4.87 billion in revenue globally in the second quarter. The drug, which treats rheumatoid arthritis and Crohn's disease, costs upwards of $60,000 a year. So it may come as no surprise that Humira is on the list of the 25 most costly drugs for Oregon health insurers in 2018. The combined list is based on the rankings submitted by nine insurance comp anies and takes into account total annual spending,… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - August 20, 2019 Category: Biotechnology Authors: Elizabeth Hayes Source Type: news